How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in Wyoming

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are both precursors that the body can convert into nicotinamide adenine dinucleotide (NAD+), a coenzyme used in energy metabolism and DNA repair. They are chemically related but not the same molecule, and as of this writing they sit on opposite sides of a regulatory line in the United States, including in Wyoming. NR is sold over the counter as a dietary supplement (brands include Tru Niagen). NMN is not currently marketable as a dietary supplement in the US, which is why NMN access runs through a prescription and a compounding pharmacy rather than a retail shelf.

The direct answer: In Wyoming, NR can be purchased without a prescription today at retail stores, online, or through a pharmacy, because the FDA has not removed it from the dietary supplement category. NMN generally cannot be sold that way; the FDA stated in 2022 that NMN was first studied as an investigational new drug, which under the Food, Drug, and Cosmetic Act excludes it from the dietary supplement definition (FDA, Dietary Supplements, accessed for this article; verify current status before purchase, as this determination has been contested and could change). Because of that exclusion, most people who want NMN specifically obtain it as a compounded preparation from a 503A pharmacy after a prescriber's evaluation, typically by telehealth. This is off-label, prescription-based access to a compounded product, not an FDA-approved drug and not a supplement purchase.

The real question is not "is it legal" but "does the prescription pathway buy you anything"

Both molecules raise NAD+ levels in small human trials, and no large trial has directly compared NMN against NR head to head to determine whether either produces meaningfully better clinical outcomes. Given that, the decision a Wyoming resident actually faces is not whether NMN is obtainable (it is, through telehealth and a 503A pharmacy) but whether the added cost, consultation, and lab testing that come with prescription NMN provide a benefit over simply buying NR over the counter. The evidence available today does not clearly answer that question, and claims that NMN is superior to NR for a given goal should be treated as plausible hypotheses, not settled fact.

What is established, what is plausible, and what is not established

Established:

• NR is legally sold as a dietary supplement in the US and in Wyoming; NMN is not currently sold that way because of the FDA's 2022 position on its investigational-drug history (FDA, Dietary Supplements).
• 503A compounding pharmacies may prepare patient-specific formulations, including NMN, when a licensed prescriber issues a valid prescription (FDA, Compounding Laws and Policies).
• Small randomized trials in humans have reported that oral NMN and oral NR each raise blood NAD+ or NAD+ metabolite levels compared with placebo over several weeks. One frequently cited trial (Yoshino et al., published in Science, 2021) reported improved skeletal muscle insulin sensitivity in postmenopausal women with prediabetes given NMN; another (Martens et al., published in Nature Communications, 2018) reported increased whole-blood NAD+ in healthy middle-aged and older adults given NR. These are individual trial results, not confirmed by large replication studies, and the exact figures should be checked against the original papers before being cited as a fixed claim.
• Short-term safety data from published human trials, generally covering weeks to a few months, have not reported serious adverse events for either molecule at the doses studied. Long-term (multi-year) human safety data do not yet exist for either NMN or NR.

Plausible but unproven:

• That NMN and NR differ meaningfully in tissue-level effects or clinical benefit. Some researchers have proposed this based on differences in cellular uptake pathways, but no controlled human trial has tested the hypothesis directly.
• That combining NMN and NR produces additive benefit over either alone. No trial evidence supports this; it increases cost without a demonstrated advantage.
• That routine NAD+ metabolite blood testing meaningfully changes clinical outcomes rather than simply tracking a biomarker. This is common practice among longevity-focused clinics but is not an established standard of care.

Not established:

• Safety in pregnancy or lactation. No adequate human safety data exist for either compound in these populations; the cautious and standard clinical position is to avoid use.
• A superior dose, frequency, or formulation (capsule vs. sublingual) for either compound in humans.
• Any FDA-approved indication for either molecule. Current human use in this context is off-label prescribing of a compounded preparation (NMN) or unregulated supplement use (NR), not treatment of a diagnosed, FDA-recognized condition.

How access actually works for a Wyoming resident

For NR: No prescription or consultation is required. It is purchased like any other dietary supplement, from a retailer, online store, or pharmacy that stocks it. Dietary supplements are not FDA-approved for safety or efficacy before sale; manufacturers are responsible for ensuring their products are not adulterated, and enforcement is after the fact.

For NMN: Access generally requires a licensed prescriber's evaluation, most often by telehealth given how thinly compounding-experienced prescribers are distributed, followed by a prescription sent to a 503A compounding pharmacy. Wyoming permits telehealth prescribing of non-controlled substances, and NMN is not a scheduled or controlled substance, but the exact conditions (in-person exam requirements, interstate licensure compact rules, nurse practitioner collaborative-agreement terms) are governed by Wyoming medical and pharmacy board rules that change over time and should be confirmed directly with the Wyoming State Board of Medicine, the Wyoming State Board of Nursing, or the Wyoming State Board of Pharmacy rather than assumed from a general article. A specific statutory citation is not reproduced here because it could not be verified against a primary legal source for this draft.

Baseline lab work before starting an NAD+ precursor commonly includes a comprehensive metabolic panel and complete blood count, since both molecules are processed through the liver and cleared by the kidneys. Some clinics also offer NAD+ metabolite panels to establish a baseline and re-test later; this is common clinical practice at longevity-focused clinics, not a required or guideline-endorsed standard.

Cost and coverage: what changes over time

Neither NMN nor NR is covered by Wyoming Medicaid or by typical commercial insurance formularies, because NMN lacks an FDA-approved indication and NR is a supplement rather than a covered prescription drug. This is the general pattern as of this writing; individual plan formularies, Medicaid preferred drug lists, and cash prices at specific pharmacies change and should be confirmed directly rather than assumed from this article. HSA/FSA eligibility for compounded preparations and supplements varies and is worth confirming with a tax professional or plan administrator before assuming reimbursement.

Safety, contraindications, and when to involve a clinician urgently

People with active liver disease, those undergoing chemotherapy, and those on narrow-therapeutic-index medications such as warfarin should discuss NAD+ precursor use with their treating physician before starting, since NAD+ metabolism runs through the liver and could theoretically interact with hepatic drug-metabolizing pathways; this is a theoretical caution based on metabolic biology rather than a documented clinical interaction study. Anyone who develops jaundice, unusual bruising or bleeding, severe abdominal pain, or signs of an allergic reaction after starting either compound should stop the product and seek medical care rather than waiting for a scheduled follow-up. Pregnant or breastfeeding individuals should avoid both NMN and NR given the absence of human safety data, consistent with general precautionary guidance for unproven supplements and off-label compounded preparations during pregnancy.

Verification checklist: stable facts vs. facts that expire

Use this before acting on anything in this article or in marketing material from a telehealth provider or compounding pharmacy.

Stable, federal or clinical-evidence facts (unlikely to change quickly; still confirm the date of your source):

• Whether NMN is currently excluded from the FDA's dietary supplement definition, check the FDA's dietary supplement page directly, since this determination has been legally contested.
• Whether NR remains classified as a dietary supplement rather than a drug.
• The general 503A compounding framework (patient-specific prescription required) under the FD&C Act.
• The existence (not the precise numeric results) of small published human trials showing NAD+ increases with oral NMN or NR.
• The absence of long-term (multi-year) human safety data for either compound.

Date-sensitive facts you must re-verify before paying or prescribing (do not rely on any article, including this one, for these):

• Whether a specific Wyoming-licensed telehealth platform's prescriber holds an active license or interstate compact authorization this month.
• Whether a specific compounding pharmacy currently holds a nonresident pharmacy license from the Wyoming State Board of Pharmacy.
• Current cash price for a specific NMN formulation, dose, and pharmacy; prices are not fixed and vary by supplier.
• Current shipping timelines from a specific pharmacy to a specific Wyoming ZIP code.
• Whether your specific insurance plan or Wyoming Medicaid has changed its coverage position on NMN or NR.
• Whether a specific brand's NR product has had any FDA safety communication, recall, or label change.
• Current Wyoming statutory or board-rule language governing telehealth prescribing, in-person exam requirements, and nurse practitioner collaborative agreements; laws and board rules change and should be read from the Wyoming Legislature's website or the relevant licensing board, not summarized secondhand.

If a provider, pharmacy, or ad cannot answer the second list with a current, checkable source, treat their other claims with more caution.

Common questions

Do I need a prescription for NR in Wyoming? No. NR is sold as a dietary supplement and can be purchased without a prescription, subject to the general caveat that dietary supplements are not FDA-approved for safety or effectiveness before sale.

Is NMN legal to obtain in Wyoming? Yes, as a compounded preparation with a valid prescription from a licensed prescriber, filled by a 503A pharmacy. It is not legal to sell as an over-the-counter dietary supplement under current FDA policy, and that policy should be confirmed as current before you rely on it.

Does insurance or Wyoming Medicaid cover NMN or NR? Generally no, for either compound, based on the current absence of an FDA-approved indication for NMN and the supplement classification of NR. Confirm with your specific plan, since formularies change.

Is NMN proven to work better than NR? No head-to-head human trial has established that one is superior to the other for a given outcome. Small separate trials of each have reported NAD+ increases and some secondary benefits, but comparing across separate trials is not the same as a direct comparison, and the clinical significance of any difference is unclear.

What should prompt me to stop and seek medical care rather than just messaging my telehealth provider? New jaundice, unusual bleeding or bruising, severe abdominal pain, or signs of an allergic reaction (swelling, difficulty breathing, hives) after starting either compound warrant urgent evaluation rather than waiting for a routine follow-up.

References

• U.S. Food and Drug Administration. Dietary Supplements. https://www.fda.gov/food/dietary-supplements
• U.S. Food and Drug Administration. Human Drug Compounding: Compounding Laws and Policies (Section 503A). https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
• U.S. Food and Drug Administration. GRAS Notice Inventory. https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory

Study citations referenced by name in the text (Yoshino et al., Science, 2021; Martens et al., Nature Communications, 2018) are described from memory of publicly reported findings and could not be linked to a verified primary-source URL for this draft. An editor should locate and confirm the exact papers, sample sizes, and effect sizes in PubMed before publication, and any numeric claims currently phrased approximately should be tightened or removed based on that verification.